NCT05728502 - An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China | Biotech Hunter

Enrollment

2,400

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Chronic Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Vericiguat (Verquvo, BAY1021189)

Dosage at the discretion of the treating physician, based on the recommendations written in the product information.

DRUG

Standard of Care (SoC)

Dosage at the discretion of the treating physician.

Trial Locations (1)

RECRUITING

Chinese Registries, Multiple Locations